Dual orexin receptor antagonist
Daridorexant
Brand names: Quviviq
Adult dose
Dose: 50mg PO 30 min before bedtime
Route: Oral
Frequency: OD nocte
Clinical pearls
- NICE TA922: chronic insomnia ≥3 nights/week ≥3 months when CBT-I unavailable or ineffective
- Lower dependence/abuse potential vs Z-drugs / benzodiazepines
- DVLA: warn re next-day driving impairment
Contraindications
- Narcolepsy
- Severe hepatic impairment
- Concurrent strong CYP3A4 inhibitors
- Hypersensitivity
Side effects
- Headache
- Daytime drowsiness
- Fatigue
- Sleep paralysis / hypnagogic hallucinations
- Complex sleep behaviours (rare)
Interactions
- Strong CYP3A4 inhibitors/inducers
- Other CNS depressants
Monitoring
- Sleep response
- Daytime function
- Mental health
Reference: BNF; NICE TA922; NICE CKS Insomnia; DVLA; SmPC; https://bnf.nice.org.uk/drugs/daridorexant/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF